Table 2. Patients characteristics: Association of Shh expression with the clinicopathological outcome of 400 patients with breast cancer.
| Characteristics | n = 400 | Shh (+) >25% expression | Shh(−) <25% expression | p-values |
|---|---|---|---|---|
| Age | 0.8682/0.9185a | |||
| <40 | 167(41.75) | 96(24.0) | 71(17.75) | |
| >40 | 233(58.25) | 132(33.0) | 101(25.25) | |
| Menopausal status | 0.0021/0.0031a | |||
| Premenopausal | 147(36.75) | 79(19.75) | 68(17.0) | |
| Postmenopausal | 253(63.25) | 146(61.5) | 107(26.75) | |
| Tumor stage | 0.0040/0.0040a | |||
| pT1 | 76(19.0) | 22(5.5) | 54(13.5) | |
| pT2 | 184(46.0) | 89(22.25) | 95(23.75) | |
| pT3 | 112(28.0) | 42(10.5) | 70(17.5) | |
| pT4 | 28(7.0) | 12(3.0) | 16(4.0) | |
| Tumor grade | 0.0384/0.0430a | |||
| G1 | 51(12.75) | 20(5.0) | 31(7.75) | |
| G2 | 264(66.0) | 121(30.25) | 143(35.75) | |
| G3 | 85(21.25) | 24(6.0) | 61(15.25) | |
| Receptors status Estrogen | 0.0001/0.0001a | |||
| Positive | 211(54.24) | 103(26.47) | 108(27.76) | |
| Negative | 178(45.76) | 52(13.37) | 178(45.76) | |
| Progesterone | 0.0001/0.0001a | |||
| Positive | 187(64.48) | 76(26.21) | 111(38.28) | |
| Negative | 103(35.52) | 12(4.14) | 91(31.38) | |
| HER2/Neu | 0.4223/0.4960a | |||
| Positive | 103(46.82) | 61(27.73) | 42(19.10) | |
| Negative | 117(53.18) | 63(63.64) | 54(24.55) | |
| Molecular classification | 0.0001/0.0001a | |||
| Triple negative | 113(28.25) | 64(16.0) | 49(12.25) | |
| Non-triple negative | 287(72.0) | 26(6.6) | 261(65.25) | |
| Distant metastasis | 0.0001/0.0001a | |||
| Positive | 120(30.0) | 75(18.75) | 45(11.25) | |
| Negative | 280(70.0) | 104(26.0) | 176(44.0) | |
| Local recurrence | 0.0035/0.0047a | |||
| Yes | 87(21.75) | 52(13.0) | 35(8.75) | |
| No | 313(78.25) | 163(40.75) | 50(37.5) |
Significance level: p<0.05 (a-Fisher Exact Test p-values).